Unfit sufferers also have the choice of venetoclax plus obinutuzumab (VO) as frontline therapy. This is based with a period III trial that in comparison VO with ClbO in elderly/unfit patients.113 VO was exceptional regarding response price and development-no cost survival, and experienced a similar safety profile. In this demo VO was administered f